资产负债表（Navidea Biopharmaceuticals Inc）
| 2023年三季报 | 2023年中报 | 2023年一季报 | 2022年年报 | 2022年三季报 | 2022年中报 | 2022年一季报 | |
|---|---|---|---|---|---|---|---|
| 截止日期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 |
| 报表类型 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 |
| 报表年结日 | 1231 | 1231 | 1231 | 1231 | 1231 | 1231 | 1231 |
| 原始币种 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 |
| 上市前/上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 |
| 流动资产： | |||||||
| 现金及现金等价物(元) | 3,864,822.00 | 6,143,869.00 | 33,795.00 | 1,995,860.00 | 4,600,791.00 | 328,012.00 | 1,217,114.00 |
| 应收账款及票据(元) | 30,870.00 | 44,712.00 | 31,043.00 | 630.00 | 155,189.00 | 30,069.00 | 115,845.00 |
| 预付款项及其他应收款流动(元) | 146,593.00 | 355,215.00 | 672,060.00 | 780,110.00 | 150,125.00 | 496,989.00 | 667,439.00 |
| 存货(元) | 460,746.00 | 460,746.00 | 460,636.00 | 427,344.00 | 193,806.00 | 315,670.00 | 322,992.00 |
| 流动资产合计(元) | 4,503,031.00 | 7,004,542.00 | 1,197,534.00 | 3,203,944.00 | 5,099,911.00 | 1,170,740.00 | 2,323,390.00 |
| 非流动资产： | |||||||
| 物业、厂房及设备(元) | 733,145.00 | 733,145.00 | 734,870.00 | 835,845.00 | 835,845.00 | 821,416.00 | 908,322.00 |
| 无形资产(元) | 1,320,428.00 | 1,061,534.00 | 1,239,477.00 | 1,215,604.00 | 1,143,814.00 | - | - |
| 非流动资产其他项目(元) | -857,810.00 | -579,409.00 | -804,295.00 | -883,787.00 | -821,138.00 | 511,549.00 | 370,413.00 |
| 非流动资产合计(元) | 1,195,763.00 | 1,215,270.00 | 1,170,052.00 | 1,167,662.00 | 1,158,521.00 | 1,332,965.00 | 1,278,735.00 |
| 总资产(元) | 5,698,794.00 | 8,219,812.00 | 2,367,586.00 | 4,371,606.00 | 6,258,432.00 | 2,503,705.00 | 3,602,125.00 |
| 流动负债： | |||||||
| 融资租赁负债流动(元) | 10,427.00 | 19,030.00 | 10,372.00 | 18,976.00 | 27,346.00 | 118,409.00 | 198,140.00 |
| 应付账款及票据(元) | 3,319,700.00 | 3,326,886.00 | 3,514,200.00 | 2,666,151.00 | 1,738,519.00 | 2,426,652.00 | 1,678,907.00 |
| 其他应付款及应计费用(元) | 3,848,443.00 | 4,159,946.00 | 4,925,845.00 | 6,456,762.00 | 5,866,992.00 | 2,776,924.00 | 3,023,221.00 |
| 递延收入流动(元) | 800,000.00 | 800,000.00 | 800,000.00 | 800,000.00 | 800,000.00 | - | - |
| 流动负债合计(元) | 7,978,570.00 | 8,305,862.00 | 9,250,417.00 | 9,941,889.00 | 8,432,857.00 | 5,321,985.00 | 4,900,268.00 |
| 非流动负债： | |||||||
| 融资租赁负债非流动(元) | 269.00 | 534.00 | 926.00 | 1,312.00 | 1,690.00 | 2,062.00 | 11,299.00 |
| 应付账款及票据非流动(元) | - | - | 1,963,866.00 | 1,871,715.00 | 1,791,001.00 | 720,305.00 | - |
| 递延收入非流动(元) | 700,000.00 | 700,000.00 | 700,000.00 | 700,000.00 | 700,000.00 | 700,000.00 | 800,000.00 |
| 非流动负债合计(元) | 700,269.00 | 700,534.00 | 2,664,792.00 | 2,573,027.00 | 2,492,691.00 | 1,422,367.00 | 811,299.00 |
| 总负债(元) | 8,678,839.00 | 9,006,396.00 | 11,915,209.00 | 12,514,916.00 | 10,925,548.00 | 6,744,352.00 | 5,711,567.00 |
| 股东权益： | |||||||
| 普通股(元) | 291,081.00 | 287,146.00 | 223,848.00 | 223,684.00 | 223,148.00 | 221,361.00 | 221,354.00 |
| 优先股(元) | 16.00 | 101.00 | 13.00 | 13.00 | 3.00 | 27.00 | 72.00 |
| 股本溢价(元) | 382,345,740.00 | 382,287,796.00 | 379,414,977.00 | 379,343,124.00 | 379,337,227.00 | 372,019,758.00 | 371,151,466.00 |
| 留存收益(元) | -385,909,398.00 | -383,654,144.00 | -389,478,978.00 | -388,002,649.00 | -384,520,021.00 | -376,774,310.00 | -373,774,852.00 |
| 归属于母公司股东权益其他项目(元) | - | - | - | - | 10.00 | - | - |
| 归属于母公司股东权益(元) | -3,272,561.00 | -1,079,101.00 | -9,840,140.00 | -8,435,828.00 | -4,959,633.00 | -4,533,164.00 | -2,401,960.00 |
| 少数股东权益(元) | 292,516.00 | 292,517.00 | 292,517.00 | 292,518.00 | 292,517.00 | 292,517.00 | 292,518.00 |
| 股东权益合计(元) | -2,980,045.00 | -786,584.00 | -9,547,623.00 | -8,143,310.00 | -4,667,116.00 | -4,240,647.00 | -2,109,442.00 |
| 负债及股东权益合计(元) | 5,698,794.00 | 8,219,812.00 | 2,367,586.00 | 4,371,606.00 | 6,258,432.00 | 2,503,705.00 | 3,602,125.00 |
| 公告日期 | 2023-11-14 | 2023-08-11 | 2023-05-11 | 2023-03-27 | 2022-11-14 | 2022-08-15 | 2022-05-16 |
| 会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 |
| 审计意见 | |||||||
| 核数师 |